Fundraising Fox
/Companies
Sign in

Akanocure Pharmaceuticals

West Lafayette, US · Founded 2014 · 1 known investors

Find your way into Akanocure Pharmaceuticals

Sign up to see every warm intro you have to Akanocure Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Akanocure Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Akanocure is a drug development company using a proprietary chemistry platform to create novel small-molecule therapies, with a focus on orphan and unmet needs in oncology and blocking metastatic processes. Its work spans chemical methodology development and classic drug discovery for cancer treatments.

BiotechHealthtech

Founders & leadership

Akanocure Pharmaceuticals was founded in 2014 by Philip L. Fuchs, Mohammad N. Noshi, and Sherine M. Abdelmawla.

PL
Philip L. FuchsCo-founder
MN
Mohammad N. NoshiCo-founder
SM
Sherine M. AbdelmawlaCo-founder

Investors · 1

Reported raises · per SEC filings

Form D private placements
▶$1MofferedMar 2015 · Pharmaceuticals
Officers, directors & promoters on the filing
  • Philip L. FuchsExecutive Officer, Director
  • Mohammad N. NoshiExecutive Officer, Director
  • Sherine M. AbdelmawlaExecutive Officer, Director
Offering amount
$1M
Minimum investment
$25K
Incorporated
Limited Liability Company, Indiana, 2014
Federal exemptions
04
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 8

Onkure Therapeutics IncOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
NovoCureNovocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
NextCureNextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Flavocure BiotechFlavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
UniqureuniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
Kura OncologyKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.

Companies working in the same space as Akanocure Pharmaceuticals.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase I2021$256K
National Science FoundationPhase II2020$950K
National Science FoundationPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Akanocure Pharmaceuticals do?
Akanocure is a drug development company using a proprietary chemistry platform to create novel small-molecule therapies, with a focus on orphan and unmet needs in oncology and blocking metastatic processes. Its work spans chemical methodology development and classic drug discovery for cancer treatments.
Who founded Akanocure Pharmaceuticals?
Akanocure Pharmaceuticals was founded by Philip L. Fuchs, Mohammad N. Noshi, Sherine M. Abdelmawla in 2014.
Who are Akanocure Pharmaceuticals's investors?
Akanocure Pharmaceuticals's investors include Elevate Ventures.
Where is Akanocure Pharmaceuticals headquartered?
Akanocure Pharmaceuticals is headquartered in West Lafayette, US.